HIV Infections
Conditions
Keywords
HIV, treatment naïve
Brief summary
The primary objective of the trial is: • to evaluate the change from baseline in plasma viral load with placebo and one of up to 4 dose regimens of RDEA806. The secondary objectives are: Efficacy * to describe the nadir of the plasma viral load * to describe the DAVG * to assess the proportion of subjects who reached a drop in viral load of 0.5 log, 1 log, or reach an undetectable viral load * to assess the plasma viral load decay rate * to evaluate immunologic changes (as measured by CD4 and CD8 cells) * to evaluate the genotypic and phenotypic pattern of the virus Pharmacokinetics * to evaluate the pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of RDEA806 Safety * to evaluate the safety and tolerability of bid and qd dosing of RDEA806 as monotherapy
Interventions
DRUGRDEA806 400 mg
DRUGPlacebo
Placebo
DRUGRDEA806 1000 mg
DRUGRDEA806 600 mg
DRUGRDEA806 800 mg
Sponsors
Ardea Biosciences, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Documented chronic HIV-1 infection * HIV-1 plasma viral load at screening visit above 5000 HIV-1 RNA copies/ml * Male, aged above 18 years and less than 65 years of age * Adequate method of birth control * Subject has never received an antiretroviral agent (NRTI, NNRTI, PI, entry inhibitor or integrase inhibitor) for the treatment of HIV and agrees not to start antiretroviral therapy prior to enrollment or subject has only received a short course of treatment for less than 14 days and has been off treatment for at least 8 weeks * Subject has no primary mutation in the reverse transcriptase (RT) gene associated with resistance to RT inhibitors and no major mutation in the protease gene associated with resistance to PIs determined by genotypic resistance testing at screening
Exclusion criteria
* History or suspicion of alcohol or drug abuse which in the Investigator's opinion may lead to non-compliance * CD4 count \< 350 cells/mm3 * Life expectancy of less than 6 months * Receipt of an investigational drug within 30 days prior to the trial drug administration * Receipt of any vaccine within 30 days of screening visit * Acute HIV-1 infection (seroconversion illness) * Acute hepatitis A or acute or chronic hepatitis B or C infection * Currently active acquired immune deficiency syndrome (AIDS)-defining illness (Category C conditions according to the Centers for Disease Control \[CDC\] Classification System for HIV Infection 1993) * No clinically relevant laboratory abnormalities Renal impairment: serum creatinine \> 1.5 x ULN * Febrile illness within 120 hours prior to dosing * History of severe drug allergy or hypersensitivity * Significant cardiac dysfunction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in HIV plasma viral load | 9 days |
Secondary
| Measure | Time frame |
|---|---|
| Safety will be assessed as adverse and HIV related events, clinical laboratory test results(hematology, chemistry, urinalysis), vital signs, 12-lead electrocardiograms (ECGs), and physical examination | 22 days |
| Pharmacokinetics and Resistance | 22 days |
Countries
Germany, United Kingdom
Outcome results
None listed